318 773

Cited 0 times in

Cited 2 times in

HLA-I-restricted CD8+ T cell immunity may accelerate tumorigenesis in conjunction with VHL inactivation

DC Field Value Language
dc.contributor.authorPark, B.-
dc.contributor.authorHeo, Seok Jae-
dc.contributor.authorLee, Y.J.-
dc.contributor.authorSeo, M.-K.-
dc.contributor.authorHong, J.-
dc.contributor.authorShin, E.-C.-
dc.contributor.authorJung, In Kyung-
dc.contributor.authorKim, Sang woo-
dc.date.accessioned2022-08-23T00:39:12Z-
dc.date.available2022-08-23T00:39:12Z-
dc.date.created2022-10-12-
dc.date.issued2022-06-
dc.identifier.issn2589-0042-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189547-
dc.description.abstractCD8+ T cells recognize and kill tumor cells with HLA-I tumor antigens in early tumorigenesis, the efficiency of which differs according to antigen-recognition coverage, as shown in earlier tumor onset in HLA-I homozygosity. However, the universality of these associations remains unknown. Here, we assessed the tumor type and driver mutation specificity in the association between tumor onset age and HLA-I zygosity. Statistical analyses identified an unexpected negative relationship in tumors with VHL biallelic loss, wherein HLA-I heterozygosity was associated with earlier tumor onset, while all others showed either no or a positive association. Testing on an independent dataset reproduced the VHL-dependent acceleration of tumor onset in the HLA-I heterozygous group, confirming the association. Further speculation proposed VEGF-A-mediated T cell exhaustion under VHL inactivation as a potential mechanism. Our findings suggest that CD8+ T cell immunity in early tumor suppression can be conditional to the genetic status of tumors and may even lead to adverse consequences.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherCell Press-
dc.relation.isPartOfIscience-
dc.relation.isPartOfISCIENCE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleHLA-I-restricted CD8+ T cell immunity may accelerate tumorigenesis in conjunction with VHL inactivation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Biomedical Systems Informatics (의생명시스템정보학교실)-
dc.contributor.googleauthorPark, B.-
dc.contributor.googleauthorHeo, Seok Jae-
dc.contributor.googleauthorLee, Y.J.-
dc.contributor.googleauthorSeo, M.-K.-
dc.contributor.googleauthorHong, J.-
dc.contributor.googleauthorShin, E.-C.-
dc.contributor.googleauthorJung, In Kyung-
dc.contributor.googleauthorKim, Sang woo-
dc.identifier.doi10.1016/j.isci.2022.104467-
dc.relation.journalcodeJ03874-
dc.identifier.eissn2589-0042-
dc.subject.keywordCancer-
dc.subject.keywordComponents of the immune system-
dc.subject.keywordImmunology-
dc.contributor.alternativeNameKim, Sang Woo-
dc.contributor.affiliatedAuthorPark, B.-
dc.contributor.affiliatedAuthorHeo, Seok Jae-
dc.contributor.affiliatedAuthorSeo, M.-K.-
dc.contributor.affiliatedAuthorHong, J.-
dc.contributor.affiliatedAuthorJung, In Kyung-
dc.contributor.affiliatedAuthorKim, Sang woo-
dc.identifier.scopusid2-s2.0-85131400813-
dc.identifier.wosid001005703000010-
dc.citation.volume25-
dc.citation.number6-
dc.identifier.bibliographicCitationIscience, Vol.25(6), 2022-06-
dc.identifier.rimsid75884-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorCancer-
dc.subject.keywordAuthorComponents of the immune system-
dc.subject.keywordAuthorImmunology-
dc.type.docTypeArticle-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.articleno104467-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.